Search Results
Your search for all items matches 585 pages
Showing 551 - 585Prolonged Sedentary Behavior Linked to Recurrence of Precancerous Colorectal Tumors in Men
Men who spend the most time engaged in sedentary behaviors are at greatest risk for recurrence of colorectal adenomas, benign tumors that are known precursors of colorectal cancers, according to results presented at the 12th Annual AACR International Conference on Frontiers in Cancer Prevention...
Novel Gene-Diet Interaction May Explain Association Between Red and Processed Meat Consumption and Colorectal Cancer Risk
A newly discovered potential gene-diet interaction for colorectal cancer may shed light on the statistically significant increased risk of colorectal cancer that is associated with consumption of red and processed meat, according to a study reported yesterday at the American Society of Human...
Perioperative FOLFOX4 Does Not Improve Overall Survival vs Surgery Alone in Patients With Resectable Liver Metastases From Colorectal Cancer
Previously reported results of the phase III EORTC intergroup 40983 trial showed that perioperative chemotherapy with FOLFOX4 (leucovorin, fluorouracil [5-FU], and oxaliplatin) increased progression-free survival compared with surgery alone in patients with initially resectable liver metastases...
PIK3CA Mutation Predictive of Relapse-Free Survival Benefit of Aspirin in Colorectal Cancer
Although nonsteroidal anti-inflammatory drugs such as aspirin have been shown to be protective against colorectal cancer and are associated with reduced disease recurrence and improved outcome, they are also associated with toxicities that limit their use in therapy. Recent data suggest that the...
ECC 2013: TP53 Status Predicts Benefit From Neoadjuvant Cetuximab in Rectal Cancer
In a retrospective analysis of the randomized phase II EXPERT-C trial presented at the European Cancer Congress 2013 (Abstract LBA7), TP53 emerged as a strong, independent predictive biomarker for the benefit of cetuximab (Erbitux) in high-risk, locally advanced rectal cancer, according to...
Colonoscopy Associated With Reduction in Overall, Distal, and Proximal Colorectal Cancer Incidence and Mortality
Colonoscopy and sigmoidoscopy have been shown to provide protection against colorectal cancer, but the magnitude and duration of protection, particularly against proximal colon cancer, remain undefined. A study of long-term colorectal cancer incidence and mortality after lower endoscopy reported in ...
Deficient DNA Mismatch Repair Associated With Favorable Prognosis in Proximal Tumors in Stage III Colon Cancer Patients Receiving Adjuvant FOLFOX
In an analysis reported in Journal of Clinical Oncology, Frank A. Sinicrope, MD, of the Mayo Clinic and North Central Cancer Treatment Group (NCCTG), and colleagues investigated the association of deficient DNA mismatch repair with prognosis in patients with stage III colon cancer treated with...
Widespread Contraindicated Use of Bevacizumab in Elderly Patients
In a study reported in Journal of Clinical Oncology, Dawn L. Hershman, MD, MS, of Columbia University, and colleagues assessed the use of bevacizumab in older patients with metastatic breast, lung, or colon cancer. They found that bevacizumab (Avastin) was contraindicated in approximately one-third ...
Presence of RAS Mutations in Metastatic Colorectal Cancer Predictive of Negative Response to Panitumumab/FOLFOX4 Treatment
Patients with metastatic colorectal cancer that harbors KRAS mutations in exon 2 do not benefit from anti-EGFR therapy. However, other activating RAS mutations may predict poorer outcome with anti-EGFR therapy. In an analysis reported in The New England Journal of Medicine by Jean-Yves Douillard,...
Addition of Bevacizumab to Capecitabine Improves Progression-Free Survival in Elderly Patients with Previously Untreated Metastatic Colorectal Cancer
Elderly patients are often underrepresented in clinical trials of metastatic colorectal cancer. In a phase III study (AVEX trial) reported in The Lancet Oncology, David Cunningham, MD, of Royal Marsden Hospital in London and colleagues assessed the addition of bevacizumab (Avastin) to capecitabine...
FDA Approves First Generic Capecitabine to Treat Colorectal and Breast Cancers
The U.S. Food and Drug Administration (FDA) has approved the first generic version of capecitabine (Xeloda), an oral chemotherapy agent used in the treatment of metastatic colorectal cancer and breast cancers. Teva Pharmaceuticals USA has gained FDA approval to market generic capecitabine in 150...
New Ultrasensitive Screening Method Can Detect Colon Cancer in Its Early Stages
A new ultrasensitive screening method that detects genetic variations that initiate colon cancer and can help in the detection of the cancer in its early stages could be used for noninvasive colon cancer screening, according to a study by Bettina Scholtka, PhD, Assistant Professor in the Department ...
Combined Microsatellite Instability and BRAF Status a Potential Marker of Risk Stratification in Colorectal Cancer
In a study reported in Journal of the National Cancer Institute, Paul Lochhead, MBChB,MRCP, of the Dana-Farber Cancer Institute and Harvard Medical School, and colleagues analyzed the association of microsatellite instability and BRAF status subgroups with survival in patients with colorectal...
Noninvasive Test Optimizes Colon Cancer Screening Rates
Organized mailing campaigns could substantially increase colorectal cancer screening among uninsured patients, according to a study published online in JAMA Internal Medicine. The research also suggested that a noninvasive colorectal screening approach, such as a fecal immunochemical test, might be ...
New Biomarker for Colorectal Cancer Could Help Predict Whether Disease Will Spread
Scientists have identified a protein that could play a crucial role in recognizing whether patients with colorectal cancer are candidates for chemotherapy due to a high risk of their cancer spreading, according to a new study published in the British Journal of Cancer. Scientists at the University...
Alternate-day, Low-dose Aspirin May Reduce Colon Cancer Risk
Low-dose aspirin (100 mg) taken every other day may reduce a woman’s risk of developing colon cancer, according to an observational study published in the Annals of Internal Medicine. The findings are based on a large long-term study of 38,876 healthy women enrolled in the Women’s...
Colorectal Cancer Survivors Face Increased Risk of Developing Subsequent Cancers of Different Types
According to a new study, colorectal cancer survivors face an increased risk of developing subsequent primary cancers, particularly second colorectal cancers and small intestinal cancers. These findings, published online in Cancer, may help in the development of screening guidelines for patients...
High Prediagnosis Red Meat Consumption Associated with Increased All-cause Mortality in Patients with Colorectal Cancer
There is evidence that diets high in red and processed meat are associated with increased risk of colorectal cancer. In a study reported in Journal of Clinical Oncology, Marjorie L. McCullough, ScD, and colleagues from the Epidemiology Research Program of the American Cancer Society examined the...
Volumetric Growth Rate of Small Colorectal Polyps on CT Colonography May Be Useful Risk Marker
The growth rates and clinical importance of small colorectal polyps have not been well established. In a study reported in Lancet Oncology, Perry J. Pickhardt, MD, of the University of Wisconsin School of Medicine and Public Health, and colleagues found that volumetric growth rate on computed...
BRAF Mutation Status May Have Effect on Benefit of Aspirin Use for Patients with Colorectal Cancer
In two large studies, the association between aspirin use and risk of colorectal cancer was affected by BRAF mutation status, with regular aspirin use associated with a lower risk of BRAF wild-type colorectal cancer but not with risk of BRAF-mutated cancer. The findings, published today in JAMA,...
Chemotherapy-induced Neuropathy Has Long-term Effect on Colorectal Cancer Survivors
In a study reported in Journal of Clinical Oncology, Floortje Mols, PhD, of the Center of Research on Psychology in Somatic Diseases, Tilburg University, and colleagues assessed the prevalence and severity of chemotherapy-induced neuropathy and its affect on health-related quality of life in...
Screening Colonoscopy Associated with Increased Survival Duration and Rates for Patients with Colon Cancer
Patients with colon cancer identified on screening colonoscopy appear to have lower-stage disease on presentation and better outcomes independent of their staging, according to a report published online today in JAMA Surgery. Since their introduction in 2000, National Institutes of Health...
Impact of Age on Efficacy of Newer Adjuvant Therapies in Patients with Stage II/III Colon Cancer
Available data suggest that patients with stage II/III colon cancer receive similar benefit from intravenous fluorouracil (5-FU) adjuvant therapy regardless of age. Combination regimens and oral fluoropyrimidine therapy are now standard treatments in this setting. Nadine J. McCleary, MD, MPH, and...
ASCO 2013: Genomic Heterogeneity Can Lead to the Selection of ‘Incorrect’ Targeted Inhibitors
Genomic heterogeneity within tumors and among lesions varies widely, and “discordance among lesions could lead to the selection of the ‘incorrect’ targeted inhibitor,” according to David B. Solit, MD, of Memorial Sloan-Kettering Cancer Center, who spoke at the ASCO/American...
ASCO 2013: Lung Cancer Mutations ALK and ROS1 Also Drive Colorectal Cancer
A study from the University of Colorado Cancer Center shows that the ALK and ROS1 gene rearrangements known to drive subsets of lung cancer are also present in some colorectal cancers. Results imply that drugs used to target ALK and ROS1 in lung cancer may also have applications in this subset of...
ASCO 2013: Cetuximab Offers Survival Advantage over Bevacizumab When Combined with FOLFIRI for First-line Treatment of Advanced Colorectal Cancer
First-line cetuximab (Erbitux) plus FOLFIRI chemotherapy (leucovorin, fluorouracil [5-FU], irinotecan) offered a roughly 4-month survival advantage over bevacizumab (Avastin) plus FOLFIRI for patients with KRAS wild-type metastatic colorectal cancer in the German phase III clinical trial FIRE-3. A ...
Women Smokers May Have Greater Risk for Colon Cancer Than Men
Smoking increased the risk for developing colon cancer, and female smokers may have a greater risk than male smokers, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. “Globally, during the last 50...
Adding Cetuximab to Chemotherapy Enables Select Patients with Advanced Colorectal Cancer and Liver Metastasis to Undergo Surgery
New results from a clinical trial conducted in Shanghai, China, indicate that adding cetuximab (Erbitux) to standard chemotherapy enables some patients with otherwise inoperable liver metastases due to colorectal cancer have their metastases surgically removed. Such surgery can be curative, and is...
Roswell Park Scientists Advance Findings about Novel, Low-toxicity Anticancer Agent
Researchers at Roswell Park Cancer Institute (RPCI) have found that a new formulation of a promising anticancer agent, the small chemical molecule FL118, is even more effective in controlling two types of cancer than a version reported in PLOS ONE 6 months earlier proved to be. Additional evidence...
Colon Cancer Patient Advocates and Physicians Urge Congress to Pass Bill Requiring Medicare Coverage of Virtual Colonoscopy
As Americans celebrate National Colorectal Cancer Awareness Month, the Colon Cancer Alliance, COLONTOWN—a survivor/patient support group for colorectal disease, including cancer—and the American College of Radiology call on Congress to pass the CT Colonography Screening...
Colonoscopy Screening Reduces Risk of Advanced Colorectal Cancer, Study Shows
A new study led by a researcher at the Perelman School of Medicine at the University of Pennsylvania adds support to current medical recommendations stating that colonoscopy screening substantially reduces an average-risk adult’s likelihood of being diagnosed with advanced colorectal...
Obesity, Physical Inactivity Linked with Risk for Certain Molecular Subtype of Colorectal Cancer
An increasing body mass index (BMI) was associated with a higher risk for colorectal cancer with a specific molecular characteristic, and inversely, physical activity was linked to a decreased risk for that same cancer, according to data published in Cancer Research, a journal of the American...
Researchers Identify Variations in Four Genes That Are Associated with an Increased Risk of Colorectal Cancer
An international research team co-led by cancer prevention researcher Ulrike Peters, PhD, MPH, and biostatistician Hsu Li, PhD, at Fred Hutchinson Cancer Research Center has identified variations in four genes that are linked to an increased risk of colorectal cancer. Dr. Peters and...
Bevacizumab Approved as Combination Therapy for Metastatic Colorectal Cancer after Progression on First-line Bevacizumab Therapy
On January 23, 2013, the FDA approved bevacizumab (Avastin) for use in combination with fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin based chemotherapy for the treatment of patients with metastatic colorectal cancer whose disease has progressed on a first-line bevacizumab-containing...
New Model May Help Predict Response to Chemotherapy for Colorectal Cancer
Scientists may be able to better predict which patients with colorectal cancer will respond to chemotherapy using a new mathematical model that measures the amount of stress required for a cancer cell to die without harming healthy tissue. The results of this study are published in Cancer Research, ...
